ISO 10993 Biological Evaluation Testing: A Complete Technical Guide for Medical Device Compliance

ISO 10993 biological testing is the internationally recognized framework for evaluating the biocompatibility and biological safety of medical devices prior to market authorization. This comprehensive guide explains the ISO 10993 test series, required sample preparation procedures, core biological endpoints, laboratory methods, and regulatory applications. Whether you are preparing a 510(k), CE marking, or NMPA submission, understanding ISO 10993 biological evaluation is essential for demonstrating device safety.

Technical Overview

ISO 10993 is a multi-part international standard series titled "Biological evaluation of medical devices," developed to provide a systematic, risk-based framework for assessing the potential biological hazards of medical devices and biomaterials. The standard series is maintained by ISO/TC 194 and is harmonized across major regulatory jurisdictions, including the United States FDA, the European Union under the Medical Device Regulation (MDR), China NMPA, and Japan MHLW. ISO 10993-1, the cornerstone of the series, establishes the principles of biological evaluation within a risk management process consistent with ISO 14971.

The evaluation strategy defined in ISO 10993-1 is driven by three fundamental device characteristics: the nature of body contact, the duration of contact, and the materials or chemicals involved. Based on these factors, manufacturers must determine which biological endpoints require evaluation, either through biological testing, chemical characterization with toxicological risk assessment, or justification based on existing data. The latest editions of ISO 10993-1 emphasize material chemical characterization and toxicological assessment as the first line of evaluation, reducing unnecessary animal testing in accordance with ISO 10993-2 animal welfare requirements.

• Part 1: Evaluation and testing within a risk management process
• Part 2: Animal welfare requirements
• Part 3: Tests for genotoxicity, carcinogenicity, and reproductive toxicity
• Part 4: Selection of tests for interactions with blood
• Part 5: Tests for in vitro cytotoxicity
• Part 6: Tests for local effects after implantation
• Part 7: Ethylene oxide sterilization residuals
• Part 10: Tests for skin sensitization
• Part 11: Tests for systemic toxicity
• Part 12: Sample preparation and reference materials
• Part 18: Chemical characterization of medical device materials within a risk management process
• Part 23: Tests for irritation

Devices are classified by contact category into surface-contacting devices (skin, mucosal membranes, breached surfaces), externally communicating devices (indirect blood path, tissue or bone communicating, circulating blood), and implant devices. Contact duration is classified as limited (24 hours or less), prolonged (24 hours to 30 days), or permanent (greater than 30 days). This classification matrix directly determines the minimum biological endpoints required for a compliant biological evaluation report.

Testing Samples

Finished Medical Devices

Whenever feasible, testing should be performed on the final product in its final sterilized condition, as processing, sterilization, and packaging can alter the biological response of device materials. The final device represents the worst-case configuration for extractable and leachable substances.

Device Materials and Coupons

When the complete device cannot be tested, representative material samples, coupons, or components are evaluated. Materials must be processed under identical conditions to the final product, including sterilization methods such as ethylene oxide, gamma irradiation, or steam autoclaving.

Test Extracts

For most in vitro and in vivo tests, aqueous and non-aqueous extracts are prepared according to ISO 10993-12. Standard extraction conditions include 37 degrees Celsius for 72 hours, 50 degrees Celsius for 72 hours, 70 degrees Celsius for 24 hours, or 121 degrees Celsius for 1 hour. Extraction ratios are based on device thickness: for example, a 6 square centimeter per milliliter ratio for materials less than 0.5 mm thick, 3 square centimeters per milliliter for materials 0.5 to 1.0 mm thick, and a ratio based on mass or absorptive capacity for irregularly shaped devices.

Extraction Media

• Polar media: saline solution (0.9 percent sodium chloride), culture medium without serum
• Non-polar media: sesame oil, cottonseed oil, or other vegetable oils
• Additional media when required: ethanol in water, dimethyl sulfoxide, or polyethylene glycol

Testing Items

ISO 10993-1 defines the biological endpoints that must be addressed for each device category. The core testing items performed by accredited biocompatibility laboratories include the following.

• Cytotoxicity (ISO 10993-5): In vitro assessment of cell viability and morphology using mammalian cell lines such as L929 mouse fibroblasts or BALB/3T3 cells
• Sensitization (ISO 10993-10): Evaluation of delayed-type hypersensitivity using the guinea pig maximization test, Buehler test, or murine local lymph node assay
• Irritation and intracutaneous reactivity (ISO 10993-23): Assessment of skin, ocular, mucosal, or intracutaneous irritation using in vitro reconstructed human epidermis models or rabbit models
• Acute systemic toxicity (ISO 10993-11): Single-dose or short-exposure evaluation of systemic harmful effects, typically in mice
• Subacute and subchronic toxicity (ISO 10993-11): Repeated-dose systemic toxicity studies of 14 to 90 days duration
• Genotoxicity (ISO 10993-3): Bacterial reverse mutation test (Ames assay), in vitro chromosomal aberration test, mouse lymphoma assay, and in vivo micronucleus test
• Hemocompatibility (ISO 10993-4): Hemolysis testing, thrombogenicity, complement activation, coagulation assays, and platelet interaction studies for blood-contacting devices
• Implantation testing (ISO 10993-6): Local tissue response evaluation at implantation sites for 1, 4, 12, or 26 weeks
• Ethylene oxide residuals (ISO 10993-7): Quantification of ethylene oxide, ethylene chlorohydrin, and ethylene glycol residues by gas chromatography
• Chemical characterization (ISO 10993-18): Identification and quantification of extractables, leachables, degradation products, and elemental impurities using GC-MS, LC-MS, ICP-MS, and FTIR
• Pyrogenicity and bacterial endotoxins: LAL gel-clot or kinetic assays verifying limits such as 20 EU per device or 0.5 EU per milliliter for parenteral-contact devices

Testing Methods

In Vitro Cytotoxicity

The MTT extraction test (MEM elution method) is the most widely applied cytotoxicity method. Device extracts are applied to L929 fibroblast monolayers for 24 to 48 hours, and cell viability is quantified by measuring formazan absorbance. A cell viability of 70 percent or greater relative to the negative control indicates the sample is non-cytotoxic. Qualitative morphology grading from 0 to 4 is also assigned by microscopic evaluation. Alternative methods include the direct contact test and the agar diffusion test for appropriate device geometries.

Sensitization Testing

The guinea pig maximization test (GPMT) involves intradermal induction with Freund complete adjuvant, topical challenge after two weeks, and erythema scoring at 24 and 48 hours. The Buehler closed-patch test applies repeated topical induction without adjuvant. The local lymph node assay (LLNA) measures lymphocyte proliferation in draining lymph nodes and is accepted as a refinement alternative with reduced animal use and shorter study duration.

Irritation Testing

Intracutaneous reactivity testing involves injecting polar and non-polar extracts intradermically at rabbit sites, followed by scoring erythema and edema on a 0 to 4 scale at 24, 48, and 72 hours. A combined score difference of less than 12 between sample and control sites indicates the device meets requirements. The in vitro skin irritation test using reconstructed human epidermis models, validated per ISO 10993-23, can now fully replace rabbit skin irritation testing.

Hemocompatibility Testing

Hemolysis is evaluated by direct contact or indirect extract methods using rabbit or human anticoagulated blood. After incubation at 37 degrees Celsius, free hemoglobin in the supernatant is measured spectrophotometrically at 540 nanometers. A hemolysis index below 5 percent is generally considered non-hemolytic. Devices with circulating blood contact may additionally require complement activation (C3a, SC5b-9), thrombogenicity, and coagulation pathway assessments.

Chemical Characterization and Toxicological Risk Assessment

Extractables and leachables studies are designed to simulate clinical extraction conditions using exaggerated solvents and temperatures. Detected compounds are identified against spectral libraries, quantified, and subjected to toxicological risk assessment using tolerable intake values and safety margins, following ISO 10993-17 methodologies.

Applications

ISO 10993 biological evaluation reports are mandatory technical documentation elements for medical device market access worldwide. The standard series supports manufacturers, contract developers, and testing laboratories throughout the product lifecycle, from material screening and supplier qualification to final regulatory submission and post-market change control.

• Regulatory submissions: FDA 510(k) and PMA submissions in the United States, CE technical files under EU MDR 2017/745, NMPA registration dossiers in China, and PMDA applications in Japan
• Surface-contacting devices: surgical gloves, electrodes, wound dressings, face masks, and compression bandages
• Externally communicating devices: IV catheters, infusion sets, dialyzers, blood bags, endoscopes, and cannulae
• Implant devices: orthopedic implants, cardiac stents, pacemakers, dental implants, hernia meshes, and intraocular lenses
• Material development: screening novel polymers, metals, ceramics, coatings, and biodegradable materials for biological safety
• Change management: evaluating the biological impact of material substitutions, manufacturing process changes, new sterilization methods, or alternative suppliers
• Drug-device and combination products: biocompatibility justification for device components of combination products and pharmaceutical delivery systems

FAQ

What is the difference between biological evaluation and biological testing under ISO 10993?

Biological evaluation is the overall risk management process that may combine chemical characterization, existing data review, and toxicological risk assessment, whereas biological testing refers specifically to laboratory tests performed to address specific endpoints. Not every endpoint requires new testing; some can be justified through documented material data and risk analysis.

How do I determine which ISO 10993 tests my device requires?

Begin with the classification matrix in ISO 10993-1 Annex A based on body contact type and contact duration. For example, a limited-duration skin-contact device typically requires cytotoxicity, sensitization, and irritation testing, while a permanent blood-contact implant may require the full endpoint panel including genotoxicity, implantation, and chronic toxicity. A formal Biological Evaluation Plan (BEP) should document the rationale.

How long do ISO 10993 tests take?

Typical turnaround times are 1 to 2 weeks for in vitro cytotoxicity, 4 to 6 weeks for intracutaneous irritation, 8 to 12 weeks for guinea pig sensitization, 3 to 5 weeks for the local lymph node assay, and 4 to 12 weeks for hemolysis and acute systemic toxicity. Genotoxicity batteries and implantation studies may require 12 to 26 weeks. Planning the full evaluation program early is critical for submission timelines.

What sample quantity is needed for testing?

Sterile final devices or representative material samples must be supplied in quantities sufficient to prepare extracts at the required surface-area-to-volume ratios. As a general guideline, laboratories request 10 to 30 finished units or 20 to 60 grams of material per sample condition, depending on device size and the test panel selected.

Are in vitro alternatives accepted instead of animal tests?

Yes. Regulatory authorities increasingly accept validated in vitro methods, including reconstructed human epidermis models for skin irritation per ISO 10993-23, in vitro cytotoxicity per ISO 10993-5, and the LLNA for sensitization. FDA and EU notified bodies generally expect in vitro methods to be considered before in vivo studies in line with the 3Rs principle of replacement, reduction, and refinement.

How often must biocompatibility testing be repeated?

If the device design, materials, manufacturing process, and sterilization method remain unchanged, historical biocompatibility data remain valid. Retesting is triggered by significant changes such as new material suppliers, altered processing parameters, different sterilization modalities, or formulation changes, and the impact must be reassessed through the documented change control process.